We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Shares of Agile Therapeutics plunged more than 62 percent in early trading after the company announced this morning the U.S. Food and Drug Administration rejected its low-dose hormonal contraceptive patch called Twirla.